LCA-H10
LCA-H10 is a lithocholic acid-histidine decapeptide conjugate, a biocompatible lipid nanoparticle (LNP) additive that reduces ionizable lipid proportions, functions as an endosomal escape inducer, and enhances siRNA encapsulation. LCA-H10 increases hepatic accumulation of LNPs in mice after intravenous injection when incorporated into LiLNP-LH and reduces proinflammatory cytokines (IL-6, TNF, IL-1β) in mouse serum. LCA-H10 can be used for the research of prostate cancer.
For research use only. We do not sell to patients.
- Formula: C84H110N30O13
- Molecular Weight:1747.97
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
LiLNP-LH (containing LCA-H10) (0-187.8 nM siRNA; 5 h + 43 h) provided enhanced gene silencing activity in PC3-GFP cells compared to LiLNP and LiLNP-H, with an IC50 of 216.9 nM[1].
LiLNP-LH (containing LCA-H10) (0.3 μg/mL siRNA (PC3); 1.5 μg/mL siRNA (HepG2); 5-6 h) showed comparable intracellular uptake to HiLNP in HepG2 cells and similar uptake to LiLNP in PC3 cells[1].
LiLNP-LH (containing LCA-H10) (0.9% molar ratio) achieved high siRNA encapsulation efficiency (83.7%) comparable to HiLNP despite a low ionizable lipid proportion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (6 weeks old, female)[1]
-
Dosage:40 μg siRNA per mouse (biodistribution); 2 mg/kg siRNA (cytokine analysis)
-
Administration:i.v.
-
Result:Exhibited 4.6× 10¹⁰ total flux in the liver (1.6-fold higher than HiLNPs) and 50.4 × 10² RFI/mg organ in liver homogenates. Reduced serum IL-6 levels to 144.1 pg/mL (30.6-fold lower than HiLNPs), TNF levels by 29.9-fold, and IL-1β levels by 14.5-fold compared to HiLNPs.
Chemical Information
-
Molecular Weight 1747.97
-
Formula C84H110N30O13
-
Sequence
LCA-His-His-His-His-His-His-His-His-His-His
-
Sequence Shortening
LCA-HHHHHHHHHH
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)